The European Medicines Agency (EMA) plans to speak next week on the Janssen (Johnson & Johnson) vaccine against Covid-19, the use of which has been suspended in the United States and South Africa due to the rare occurrence of serious blood clots.
Read also: The Johnson & Johnson vaccine will be administered as planned to those over 55 in France
"
The EMA is investigating all reported cases and will decide whether regulatory action is needed
" and "
currently plans to issue a recommendation next week
," said the regulator, who for now remains of the view that the benefits l outweigh the risks.
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/KMEYMJKESBAZBE4MRBAM4TGHIQ.jpg)
